Syntimmune, Inc.
http://syntimmune.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Syntimmune, Inc.
J&J Seeks Command Position In FcRn Space With Momenta Buyout
J&J will pay about $6.5bn to acquire Momenta and its potential “pipeline in a pathway” with nipocalimab. Analysts expect this deal may lead to further M&A activity in the anti-FcRn space.
Finance Watch: Polaris Piles On As Multiple Life Science VCs Raise New Funds
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
Scandinavia Serves Up Two Partners For Alexion, In Its Rare Disease Sweet-Spot
Leading US biotech Alexion is to collaborate with two European biotechs, Affibody and Zealand, on early-stage products for rare diseases, involving bivalent antibody-mimetic scaffolds and novel peptides.
Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna
Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.